193 related articles for article (PubMed ID: 25521354)
1. Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.
Tay-Sontheimer J; Shireman LM; Beyer RP; Senn T; Witten D; Pearce RE; Gaedigk A; Gana Fomban CL; Lutz JD; Isoherranen N; Thummel KE; Fiehn O; Leeder JS; Lin YS
Pharmacogenomics; 2014 Dec; 15(16):1947-62. PubMed ID: 25521354
[TBL] [Abstract][Full Text] [Related]
2. Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates.
Labbé L; Sirois C; Pilote S; Arseneault M; Robitaille NM; Turgeon J; Hamelin BA
Pharmacogenetics; 2000 Jul; 10(5):425-38. PubMed ID: 10898112
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
[TBL] [Abstract][Full Text] [Related]
4. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
[TBL] [Abstract][Full Text] [Related]
5. Omission of the deconjugation step in urine analysis and the unaltered outcome of CYP2D6 phenotyping with dextromethorphan.
Basci NE; Bozkurt A; Kayaalp SO; Sayal A; Isimer A
Eur J Drug Metab Pharmacokinet; 1998; 23(1):1-5. PubMed ID: 9625265
[TBL] [Abstract][Full Text] [Related]
6. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping.
Streetman DS; Ellis RE; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 1999 Nov; 66(5):535-41. PubMed ID: 10579482
[TBL] [Abstract][Full Text] [Related]
7. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
8. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
9. Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice.
Jurica J; Bartecek R; Zourkova A; Pindurova E; Sulcova A; Kasparek T; Zendulka O
J Clin Pharm Ther; 2012 Aug; 37(4):486-90. PubMed ID: 22548589
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 phenotyping with dextromethorphan.
Wojtczak A; Rychlik-Sych M; Krochmalska-Ulacha E; Skretkowicz J
Pharmacol Rep; 2007; 59(6):734-8. PubMed ID: 18195464
[TBL] [Abstract][Full Text] [Related]
11. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
[TBL] [Abstract][Full Text] [Related]
12. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Alfaro CL; Lam YW; Simpson J; Ereshefsky L
J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
[TBL] [Abstract][Full Text] [Related]
13. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
15. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Schadel M; Wu D; Otton SV; Kalow W; Sellers EM
J Clin Psychopharmacol; 1995 Aug; 15(4):263-9. PubMed ID: 7593709
[TBL] [Abstract][Full Text] [Related]
17. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping.
Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Shirey CS; Gotschall R; Gaedigk A; Bertino JS
Pharmacogenetics; 1998 Oct; 8(5):403-10. PubMed ID: 9825832
[TBL] [Abstract][Full Text] [Related]
18. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CYP2D6 activity by bupropion.
Kotlyar M; Brauer LH; Tracy TS; Hatsukami DK; Harris J; Bronars CA; Adson DE
J Clin Psychopharmacol; 2005 Jun; 25(3):226-9. PubMed ID: 15876900
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]